TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4068237

Group type: EXPERIMENTAL
Intervention: N-CWS immunotherapy
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 276
Study: 30232083

Group type: EXPERIMENTAL
Intervention: Extensive sampling of the tubes for STICs/STILs/p53 signatures
Number of subjects: 479
Study: 27981924

Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg per night, increased to 200 mg if needed)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (received 10 mg azasetron before chemotherapy)
Number of subjects: 78
Study: 24882841

Group type: EXPERIMENTAL
Intervention: Telemedicine kinesiotherapy (using a portable device and telemonitoring infrastructure)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control kinesiotherapy (using common daily-life objects)
Number of subjects: 40
Study: 22817102

Group type: EXPERIMENTAL
Intervention: Pre- and post-operative orthogeriatric care
Number of subjects: 332
Study: 19525335

Group type: EXPERIMENTAL
Intervention: Nabilone 1-3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18718641

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 2 weeks
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 1 month
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 3 months
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 4 months
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d) for 1-4 months
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control (placebo/surgery)
Number of subjects: 307
Study: 15823654

Group type: EXPERIMENTAL
Intervention: Hand rubbing with an alcoholic solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Handwashing with unmedicated soap
Number of subjects: 50
Study: 11983645

Group type: EXPERIMENTAL
Intervention: Work and Social Adjustment Scale (WSAS)
Number of subjects: 0
Study: 10099965

Group type: EXPERIMENTAL
Intervention: buserelin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: nafarelin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: leuprorelin
Number of subjects: 60
Study: 7776647

Group type: EXPERIMENTAL
Intervention: Self-serving attributors in the conjunctive-task condition
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Additive-task participants
Number of subjects: 24
Study: 2170820

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of angiotensin II (AII)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 85812

Group type: EXPERIMENTAL
Intervention: Intravenous aminoacid infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 30
Study: 31804285

Group type: EXPERIMENTAL
Intervention: Expert modeling
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Voice-over PowerPoint
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Reading assignments
Number of subjects: 73
Study: 31131617

Group type: EXPERIMENTAL
Intervention: Lactulose 2 g/day for 2 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 28489214

Group type: EXPERIMENTAL
Intervention: Bacterial Cellulose (BC) membrane dressings
Number of subjects: 25

Group type: COMPARATOR
Intervention: Triglyceride oil dressings
Number of subjects: 25
Study: 25530275

Group type: COMPARATOR
Intervention: Propofol alone (group P)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Propofol combined with 40% nitrous oxide inhalation (group N+P)
Number of subjects: 88
Study: 24197662

Group type: EXPERIMENTAL
Intervention: Tamoxifen (4+ years)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Tamoxifen (<4 years)
Number of subjects: 690
Study: 22044787

Group type: EXPERIMENTAL
Intervention: Active navigation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Passive navigation
Number of subjects: 44
Study: 19497559

Group type: EXPERIMENTAL
Intervention: Sibutramine alone
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Lifestyle modification alone
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Sibutramine plus brief lifestyle modification
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Early weight loss
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Weight loss success at 1 year
Number of subjects: 224
Study: 17760540

Group type: EXPERIMENTAL
Intervention: Powered toothbrush and triclosan/copolymer/fluoride-containing dentifrice
Number of subjects: 160

Group type: COMPARATOR
Intervention: Manual toothbrush and standard fluoride-containing dentifrice
Number of subjects: 160
Study: 11036118

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 404

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 404
Study: 8796365

Group type: EXPERIMENTAL
Intervention: Amiodarone treatment for 6 months
Number of subjects: 20
Study: 1636873

Group type: EXPERIMENTAL
Intervention: Halofantrine (3 x 500 mg for one day)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Halofantrine (3 x 500 mg for one day + additional treatment on day 7)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Halofantrine (both regimens)
Number of subjects: 74
Study: 6148024

Group type: EXPERIMENTAL
Intervention: Permethrin-treated clothing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deet applied to exposed skin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined use of permethrin-treated clothing and deet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated clothing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Permethrin-treated uniforms
Number of subjects: 0
Study: 30721652

Group type: EXPERIMENTAL
Intervention: Premature Infant Oral Motor Intervention (PIOMI) once daily for 7 consecutive days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine care only (Control)
Number of subjects: 30
Study: 29608461

Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 2218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2218
Study: 26650971

Group type: EXPERIMENTAL
Intervention: RBP-6000 (300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydromorphone (6 mg, 18 mg)
Number of subjects: 0
Study: 24952866

Group type: EXPERIMENTAL
Intervention: Transradial PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfemoral PCI
Number of subjects: 0
Study: 22677307

Group type: EXPERIMENTAL
Intervention: Azomac® (Test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zithromax® (Reference product)
Number of subjects: 24
Study: 20722559

Group type: EXPERIMENTAL
Intervention: Checking renal function in all patients prior to angiography
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Checking both estimated glomerular filtration rate (eGFR) and serum creatinine (SCr)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Checking serum creatinine (SCr) alone
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Checking estimated glomerular filtration rate (eGFR) alone
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Checking albumin-to-creatinine (A-C) ratio
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Considering eGFR level less than 60 mL/min/1.73 m² as high risk for CIN
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Considering eGFR level less than 30 mL/min/1.73 m² as high risk for CIN
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Using only isosmolar media in high-risk patients
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Using only low osmolar media in high-risk patients
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Using either isosmolar or low osmolar media in high-risk patients
Number of subjects: 291
Study: 18587501

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15793048

Group type: EXPERIMENTAL
Intervention: Hospital-based exercise program (3 sessions per week)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Home-based exercise program (3 sessions per week)
Number of subjects: 136
Study: 12594972

Group type: EXPERIMENTAL
Intervention: Real acupuncture applied to tender points once a week for 3 weeks.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham acupuncture (no needle insertion) applied to tender points once a week for 3 weeks.
Number of subjects: 34
Study: 10073841

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin K1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous vitamin K1
Number of subjects: 0
Study: 7721614

Group type: EXPERIMENTAL
Intervention: Megestrol 40 mg three times per day by mouth
Number of subjects: 198

Group type: COMPARATOR
Intervention: Diethylstilbestrol 1 mg three times per day by mouth
Number of subjects: 198

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Megestrol
Number of subjects: 198
Study: 2047898

Group type: EXPERIMENTAL
Intervention: Active partner condition
Number of subjects: 114

Group type: COMPARATOR
Intervention: Passive partner condition
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Home monitoring (immediate)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Home monitoring (delayed)
Number of subjects: 114
Study: 30678676

Group type: EXPERIMENTAL
Intervention: Extended access to the Big White Wall (BWW) for 3 months (n=55)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Discontinuation of access to the Big White Wall (BWW) (n=57)
Number of subjects: 233
Study: 29432076

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using paclitaxel and carboplatin (3 cycles, once every 3 weeks) followed by radical hysterectomy
Number of subjects: 633

Group type: COMPARATOR
Intervention: Concomitant chemoradiation with standard cisplatin-based treatment (once every week for 5 weeks)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus surgery
Number of subjects: 633

Group type: COMPARATOR
Intervention: Concomitant chemoradiation
Number of subjects: 633
Study: 26694501

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT) - 4 sets of 30-s maximal effort, separated by 4 m 30-s rest intervals
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resistance Training (RT) - 3 sets × 10 repetitions at 80% 1RM of arm-curl exercise, performed 3 times per week for 8 weeks
Number of subjects: 20
Study: 24788282

Group type: EXPERIMENTAL
Intervention: Dietary coaching
Number of subjects: 0
Study: 23654003

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg administered 1 hour and 24 hours after phacoemulsification (Group I)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (Group II) without acetazolamide
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg (Group I)
Number of subjects: 53
Study: 20591614

Group type: EXPERIMENTAL
Intervention: Spiritually Integrated Treatment (SIT)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 125
Study: 17956647

Group type: EXPERIMENTAL
Intervention: EPA+DHA supplementation (1.5 g/d)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 16438453

Group type: EXPERIMENTAL
Intervention: Validated Arabic version of the WHO‐ILAR COPCORD Core Questionnaire
Number of subjects: 5159

Group type: EXPERIMENTAL
Intervention: Follow-up for one year with phone calls every 2 weeks
Number of subjects: 5159
Study: 12449209

Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction (CAI) module on radiographic technique
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Students who used the CAI module
Number of subjects: 59

Group type: COMPARATOR
Intervention: Students who did not view the CAI CD
Number of subjects: 59
Study: 10602978

Group type: EXPERIMENTAL
Intervention: Erbium filtration (0.1 mm added to standard filtration)
Number of subjects: 21
Study: 8751166

Group type: EXPERIMENTAL
Intervention: Oxygen saturation (Sao2) before medication
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oxygen saturation (Sao2) after medication
Number of subjects: 74

Group type: COMPARATOR
Intervention: Clinical response to treatment
Number of subjects: 74
Study: 2048049

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 0.3 micrograms/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 20
Study: 6455963

Group type: EXPERIMENTAL
Intervention: Isoniazid (oral treatment)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31791396

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for insomnia (CBTi) - six sessions
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sleep support group - six sessions
Number of subjects: 102

Group type: COMPARATOR
Intervention: Audiologically based care - two sessions
Number of subjects: 102
Study: 27491377

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (3 mg/kg of zinc sulfate monohydrate twice a day orally for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (antibiotics and supportive care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc group
Number of subjects: 0
Study: 26114468

Group type: EXPERIMENTAL
Intervention: Size Matters Handwriting Program for 40 sessions
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard instruction (Control)
Number of subjects: 207
Study: 23368685

Group type: EXPERIMENTAL
Intervention: Microneedle fractional RF plus stem cell conditioned medium
Number of subjects: 15

Group type: COMPARATOR
Intervention: Microneedle fractional RF alone
Number of subjects: 15
Study: 20971535

Group type: EXPERIMENTAL
Intervention: CCD (preOp(®), Nutricia, UK, 50 g carbohydrate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CCD/G (preOp(®), 36 g carbohydrate + 15 g glutamine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CCD/L (preOp(®), 36 g carbohydrate + 7 g lipid)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CCD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CCD/G
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CCD/L
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 10
Study: 19134240

Group type: EXPERIMENTAL
Intervention: Probiotic and LC‐PUFA-containing experimental formulas
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 142
Study: 17827461

Group type: EXPERIMENTAL
Intervention: Chemotherapy (fluorouracil and cisplatin) combined with radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cytotoxic drugs or increased radiation dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Camptothecin and taxane-based regimens combined with radiation
Number of subjects: 0
Study: 15182893

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo naltrexone (Control)
Number of subjects: 52
Study: 11641030

Group type: EXPERIMENTAL
Intervention: Erythromycin (1.5 mg/kg, 6 hourly)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9676350

Group type: EXPERIMENTAL
Intervention: Twice daily administration of sustained release theophylline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Once daily administration of sustained release theophylline
Number of subjects: 18
Study: 7986180

Group type: EXPERIMENTAL
Intervention: Adjunctive oral cabergoline (maximum dose, 5 mg/d)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Adjunctive oral cabergoline
Number of subjects: 41

Group type: COMPARATOR
Intervention: Carbidopa and levodopa without cabergoline
Number of subjects: 41
Study: 2733574

Group type: EXPERIMENTAL
Intervention: Oral iron (320 mg ferrous sulfate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 40
Study: 31575825

Group type: EXPERIMENTAL
Intervention: Caffeine 2 mg·kg‐1
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Caffeine 4 mg·kg‐1
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg·kg‐1
Number of subjects: 28

Group type: COMPARATOR
Intervention: No-placebo control
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 28
Study: 26673692

Group type: EXPERIMENTAL
Intervention: Ganglioside consumption (43 mg/d)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ganglioside consumption (43 mg/d) in patients with IBD
Number of subjects: 23
Study: 25141095

Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 168

Group type: COMPARATOR
Intervention: Metal cannula
Number of subjects: 168
Study: 23286660

Group type: EXPERIMENTAL
Intervention: Six professionally developed brochures with preconception health messages
Number of subjects: 687

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 687
Study: 20702513

Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with Bobath techniques
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bobath techniques alone (Control)
Number of subjects: 48
Study: 19565735

Group type: EXPERIMENTAL
Intervention: Combined moxibustion and medicine group (n = 22)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chinese medicine group (n = 29)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Western medicine group (n = 24)
Number of subjects: 75
Study: 16505439

Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a 180 mug once weekly for 24 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a 360 mug once weekly for 24 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a 450 mug once weekly for 24 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a (all doses)
Number of subjects: 150
Study: 14718821

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (therapy group) with physical therapy designed to strengthen calf musculature.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no specific intervention beyond Class II compression hosiery).
Number of subjects: 31
Study: 11572531

Group type: EXPERIMENTAL
Intervention: 10 mg/kg acetaminophen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9484618

Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroprotective agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMG Co‐A reductase inhibitors
Number of subjects: 0
Study: 7828215

Group type: EXPERIMENTAL
Intervention: Smoking smokers
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Abstinent smokers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 24
Study: 2892989

Group type: EXPERIMENTAL
Intervention: (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) plus calcium (1 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium alone (Control)
Number of subjects: 0
Study: 29702684

Group type: EXPERIMENTAL
Intervention: 50-50% N2O-O2 mixture
Number of subjects: 84

Group type: COMPARATOR
Intervention: 100% oxygen inhalation (Control)
Number of subjects: 84
Study: 26897518

Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream for 16 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Immediate LLETZ (standard care)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream
Number of subjects: 140
Study: 26210791

Group type: EXPERIMENTAL
Intervention: Boric acid
Number of subjects: 240

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 240
Study: 23997689

Group type: EXPERIMENTAL
Intervention: Once weekly, supervised hospital-based maintenance exercise plus home exercise for 12 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unsupervised home maintenance exercise for 12 months
Number of subjects: 48
Study: 21941220

Group type: EXPERIMENTAL
Intervention: Ketamine (intravenous loading dose 0.5 mg/kg followed by 9 μg/kg per minute for 20 mins)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg orally over 2 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketamine (0.006, 0.02, 0.06, and 0.2 mg/kg per minute) in rats
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pregabalin (0.127, 0.42, and 1.27 mg/kg per minute) in rats
Number of subjects: 48
Study: 18816801

Group type: EXPERIMENTAL
Intervention: Drawing and writing movements using a pen attached to the bottom of a finger splint
Number of subjects: 21

Group type: COMPARATOR
Intervention: Therapeutic putty to train finger movements without exercises of drawing and writing movements
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both training modalities
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Re-training
Number of subjects: 21
Study: 16470607

Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine (100 mg daily before and until at least 8 weeks after chemotherapy)
Number of subjects: 156
Study: 12857352

Group type: EXPERIMENTAL
Intervention: Digitized M-mode recordings
Number of subjects: 0

Group type: COMPARATOR
Intervention: M-mode strip chart recordings
Number of subjects: 0
Study: 10635654

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg administered at 8 a.m.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg administered at 14.00 (2 p.m.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg administered at 17.00 (5 p.m.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg administered at 20.00 (8 p.m.)
Number of subjects: 30
Study: 8942397

Group type: EXPERIMENTAL
Intervention: Pinacidil (25 mg orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1972430

Group type: EXPERIMENTAL
Intervention: Nutrient-enriched 'preterm' formula
Number of subjects: 424

Group type: COMPARATOR
Intervention: Standard 'term' formula
Number of subjects: 424
Study: 31221222

Group type: EXPERIMENTAL
Intervention: Gabapentin as add-on to morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (morphine only)
Number of subjects: 0